Experienced in Acute Myelomonocytic Leukemia

Overview

Robert Cooper is a Pediatric Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Cooper has been practicing medicine for over 36 years and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Hepatoblastoma, Ependymoma, Langerhans Cell Histiocytosis, Rhabdoid Tumor, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 68 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Acute Myelomonocytic Leukemia.

Graduate Year
1989
Specialties
Pediatric Hematology Oncology
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

SOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP
4867 W Sunset Blvd, Los Angeles, CA 90027
323-783-4011
Other Locations
SOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP
4733 W Sunset Blvd, Los Angeles, CA 90027
213-667-4784
SOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP
4950 W Sunset Blvd, Los Angeles, CA 90027
323-783-4011

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


68 Clinical Trials

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
View 49 Less Clinical Trials
Similar Doctors
Expertise in
42
conditions
Oncology | Hematology | Hematology Oncology
Expertise in
42
conditions
Oncology | Hematology | Hematology Oncology

The Regents Of The University Of California

757 Westwood Plz, 
Los Angeles, CA 
 (8.9 mi)
Languages Spoken:
English
Offers Telehealth

Herbert Eradat is an Oncologist and a Hematologist in Los Angeles, California. Dr. Eradat and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
16
conditions
Hematology Oncology | Hematology | Oncology
Expertise in
16
conditions
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (5.9 mi)
Languages Spoken:
English
Offers Telehealth

George Yaghmour is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Yaghmour and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
23
conditions
Oncology | Hematology
Expertise in
23
conditions
Oncology | Hematology

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (5.8 mi)
Languages Spoken:
English
Offers Telehealth

Syma Iqbal is an Oncologist and a Hematologist in Los Angeles, California. Dr. Iqbal and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Colorectal Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, and Neuroendocrine Tumor.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile